Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Killer Cells, Lymphokine-Activated MeSH Descriptor Data 2026


MeSH Heading
Killer Cells, Lymphokine-Activated
Tree Number(s)
A11.118.637.555.283.500
A11.118.637.555.567.537.500
A15.145.229.637.555.283.500
A15.145.229.637.555.567.537.500
A15.382.490.555.283.500
A15.382.490.555.567.537.500
Unique ID
D015979
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D015979
Annotation
if subpopulations are discussed, coordinate IM with LYMPHOCYTE SUBSETS (IM)
Scope Note
Cytolytic lymphocytes with the unique capacity of killing natural killer (NK)-resistant fresh tumor cells. They are INTERLEUKIN-2-activated NK cells that have no MAJOR HISTOCOMPATIBILITY COMPLEX restriction or need for antigen stimulation. LAK cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients.
Entry Term(s)
LAK Cells
Lymphokine-Activated Killer Cells
Previous Indexing
Killer Cells, Natural (1982-1989)
See Also
Immunotherapy, Adoptive
Interleukin-2
Public MeSH Note
90
History Note
90
Date Introduced
1990/01/01
Last Updated
2008/07/08
Killer Cells, Lymphokine-Activated Preferred
page delivered in 0.122s